Private View: Animals in Advertising

Share this article:
Evan Young
Evan Young

Borrowed interest in advertising is an occasional flashpoint for heated discussions around the proverbial water cooler. In a global sense, use of unrelated metaphor or techniques to grab attention for a brand can be a mixed bag. It can be hilarious or awe-inspiring, but if your audience doesn't connect it to the brand, then you've flopped.

Some creative professionals rail from the pulpit against use of borrowed interest. Others listen to these diatribes and shrug—meh!—then turn back to their elephant concept.

Me? I like animals. Not in the crazy cat guy sense, but for pure visual impact, animals are exceptionally fascinating to look at. Ditto for insects. Fruit. Cool robots. Clay. Yarn. Goo. Whatever.

Any of these objects might have a metaphorical hook that provides a perfect entrée to the efficacy, MOA, pharmacokinetics, or QoL impact of a brand. All is fair game, it just has to make sense.

In other words... don't give me a lung cancer Chimp. Give me an allergy Bee.

And with that segue, I present (in the above slideshow): Animals in Advertising.  

Evan Young is associate creative director at Renavatio Healthcare Communi­cations.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?